Loading...

Home
ETF
ZNTL

ZNTL

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ZNTL News

Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate

Jan 12 2026PRnewswire

Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate

Jan 12 2026Newsfilter

Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest

Jan 12 2026NASDAQ.COM

China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%

Jan 09 2026NASDAQ.COM

Zentalis Pharmaceuticals' Azenosertib Set for Key Milestones in 2026

Jan 07 2026NASDAQ.COM

Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

Nov 03 2025Newsfilter

Zentalis Pharmaceuticals Set to Attend Upcoming Investor Conferences

Nov 03 2025Newsfilter

Zentalis Pharmaceuticals to Showcase Four Azenosertib Posters at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13 2025Newsfilter

Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

Oct 01 2025Newsfilter

Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost

Sep 09 2025NASDAQ.COM

Zentalis Pharmaceuticals Names James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26 2025Newsfilter

Zentalis (ZNTL) Q2 Loss Narrows 70%

Aug 07 2025NASDAQ.COM

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 01 2025Newsfilter

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 02 2025Newsfilter

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 01 2025Newsfilter

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 01 2025Newsfilter